Gardasil Vaccine: Merck Expanding It's Market

Merck is getting a little too greedy even for a pharmaceutical company.  It has persuaded the Food and Drug Administration to fast track approval of its cervical cancer vaccine Gardasil for older women.  They are now recommending that doctors give it to their patients who are 27 to 45.

Here are three ways Gardasil benefits Merck's bottom line.

• Gardasil, already approved for females ages 9 to 26, is one of Merck's top-selling products with $1.5 billion in sales last year.
• Use among older women may generate an additional $1 billion in annual sales for Merck.
• Merck is counting on Gardasil to replace revenue lost from products losing patentent protection.

.

Merck is getting a little too greedy even for a pharmaceutical company.  It has persuaded the Food and Drug Administration to fast track approval of its cervical cancer vaccine Gardasil for older women.  They are now recommending that doctors give it to their patients who are 27 to 45.

Here are three ways Gardasil benefits Merck's bottom line.

Since Gardasil was approved the public interest group Judicial Watch has reported 1600 cases of serious adverse effects in patients who received Garasil.'

Now this drug is to be inflicted on older women. How many of them get cancer from HPV? Not many. How many NEED to be vaccinated with a vaccine that has already killed young women, has been minimally tested and is purely a vehicle to make money for Merck?

The FDA, whose job is to protect the public rather than the drug companies, have agreed to cut the approval process for Gardasil from 10 months to six months.

It's time for women to learn to say NO and for doctors to and YES to protecting the health of their patients